NCT06953882
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06953882
Title Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy (SELECT)
Acronym SELECT
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Yale University
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.